The objective of this audit is to examine the effectiveness of the procurement and contract management of onshore-manufactured antivenoms and vaccines.

Audit criteria

The ANAO proposes to examine:

  • Was the 2020–21 procurement of Seqirus antivenoms, Q fever vaccines, and influenza vaccines effective?
  • Was the 2021–22 procurement of Moderna onshore mRNA vaccines effective?

Subscribe

* indicates required

Work program portfolios

This in-progress Performance audit is featured in 2 annual audit work program portfolios: